Peter Hunt
Internal Medicine · San Francisco, CANPI 1730296484
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,768 of the $79,362 with a category attached, or 80.3%. 3 manufacturers reported payments, led by Viiv Healthcare Company at 50.0% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $1392.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$40K
- Merck$31K
- Gilead$8K
Across 16 payments — averaging $607,001 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.4M
- Gilead$3.3M
What the payments were for
- Consulting fees$63,76880%
- Travel & lodging$14,16018%
- Food & beverage$1,4352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 8 | $39,670 |
| Merck | 40 | $31,330 |
| Gilead | 9 | $8,363 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DELSTRIGO$150
How this compares
$79,362 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 46 | $192,080 |
| PifeltroDoravirine | 18 | $29,830 |
| TivicayDolutegravir Sodium | 13 | $27,854 |
| Fluconazole | 13 | $393 |
| Gabapentin | 11 | $286 |
| Bupropion Hcl SrBupropion Hcl | 13 | $89 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 13 | $40 |
| Lorazepam | 14 | $32 |
| Rosuvastatin Calcium | 13 | $21 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $8,363 | $192,08046 claims |
| MerckPifeltro | $31,330 | $29,83018 claims |
| Viiv Healthcare CompanyTivicay | $39,670 | $27,85413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.